Lack of Pharmacokinetic Interactions Between Dapagliflozin and Simvastatin, Valsartan, Warfarin, or DigoxinSreeneeranj Kasichayanula, David W. Boulton, Ming Chang et al.|Advances in Therapy|2012Cited by 62
Pharmacokinetic and Pharmacodynamic Properties of Single- and Multiple-Dose of Dapagliflozin, a Selective Inhibitor of SGLT2, in Healthy Chinese SubjectsYang Li, David W. Boulton, Haiyan Li et al.|Clinical Therapeutics|2013Cited by 43
The Clinical Development of Taldefgrobep Alfa: An Anti-Myostatin Adnectin for the Treatment of Duchenne Muscular DystrophyFrancesco Muntoni, Alberto Dubrovsky, Giridhar Tirucherai et al.|Neurology and Therapy|2024Cited by 23
Bioequivalence, Food Effect, and Steady‐State Assessment of Dapagliflozin/Metformin Extended‐release Fixed‐dose Combination Tablets Relative to Single‐component Dapagliflozin and Metformin Extended‐release Tablets in Healthy SubjectsMing Chang, David W. Boulton, Xiaoni Liu et al.|Clinical Therapeutics|2015Cited by 19
Fed and Fasted Single-dose Assessment of Bioequivalence of Dapagliflozin and Metformin Extended-release Fixed-dose Combination Tablets Relative to Single-component Dapagliflozin and Metformin Extended-release Tablets in Healthy SubjectsDavid W. Boulton, Frank LaCreta, Ming Chang et al.|Clinical Therapeutics|2015Cited by 14